SRRK•benzinga•
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Summary
Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga